Is Fulcrum Therapeutics, Inc. overvalued or undervalued?

As of 11 August 2020, Fulcrum Therapeutics, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued. Key ratios include a P/E ratio of 252, a Price to Book Value of 1.71, and an EV to Sales ratio of 2.09. In comparison to peers, Fulcrum's P/E ratio is significantly higher than Soleno Therapeutics, Inc., which has a P/E of -20.32, and Arcutis Biotherapeutics, Inc., with a P/E of -12.14, indicating a stark valuation discrepancy within the industry.
Additionally, Fulcrum's ROCE stands at a troubling -252.38%, while its ROE is a mere 0.68%, further suggesting inefficiencies in generating returns. Despite recent stock performance showing a 52.55% year-to-date return compared to the S&P 500's 2.44%, the underlying valuation metrics indicate that the stock is not justified at its current price of $7.17.